Updates

July 13, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity -500257 Subject: Business Responsibility and Sustainability Report for the financial year 2025-26 Dear Sir/Madam, Pursuant to Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose the Business Responsibility and Sustainability Report for the financial year 2025-26, which also forms part of the Integrated Report 2025-26. The above is for your information and dissemination. Thanking you, For LUPIN LIMITED AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754) Encl.: a/a. LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com Business Responsibility and Sustainability Report Lupin Limited FY 2025-2026 2 LUPIN LIMITED | Integrated Report 2025-2026 Business Responsibility and Sustainability Report 3 Business Responsibility and Sustainability Report SECTION A: GENERAL DISCLOSURES I. Details of the listed entity 1. Corporate Identity Number (CIN) of the Listed Entity L24100MH1983PLC029442 2. Name of the Listed Entity Lupin Limited 3. Year of incorporation 1983 4. Registered office address Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai - 400 055, India. 5. Corporate address Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai - 400 055, India. 6. E-mail hosecretarial@lupin.com 7. Telephone + 91 22 6640 2323 8. Website www.lupin.com 9. Financial year for which reporting is being done 1st April 2025 to 31st March 2026 10. Name of the Stock Exchange(s) where shares are listed BSE Limited National Stock Exchange of India Limited 11. Paid-up Capital INR 914.4 Million 12. Name and contact details (telephone, email address) of the person Ramesh Swaminathan, Executive Director, Global CFO and Head of IT who may be contacted in case of any queries on the BRSR report and API Plus SBU, +91 22 6640 2323, hosecretarial@lupin.com 13. Reporting Boundary Standalone 14. Name of assurance provider DNV Business Assurance India Private Limited 15. Type of assurance obtained Reasonable Assurance for Core Indicators II. Products/services 16. Details of business activities (accounting for 90% of the turnover): S. No. Description of Main Activity Description of Business Activity % of Turnover of the entity 1 Manufacture of Pharmaceuticals Manufacturing and sales of Pharmaceuticals 98.4% 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): S. No. Product/Service NIC Code % of total Turnover contributed 1 Manufacture of Pharmaceuticals 210 Medical and Healthcare 100% III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National 12 5 17 International 3 7 10 19. Markets served by the entity: a. Number of locations Locations Number National (No. of States) 28 and 6 Union Territories International (No. of Countries) 136 Our reach extends across India, providing services in every state. 4 LUPIN LIMITED | Integrated Report 2025-2026 b. What is the contribution of exports as a percentage of the total turnover of the entity? Of the total sales of INR 190,444.2 million, 58.6% comprises of export sales. c. A brief on types of customers: Lupin’s customer ecosystem is centered on patients, who are the ultimate end users of its medicines across multiple therapeutic areas. Patient access is enabled through a network of channel partners, including wholesalers, distributors, pharmacy chains, and independent retail pharmacies that ensure availability across markets. Institutional customers such as hospitals, healthcare systems and government or public health agencies procure products for large-scale and public healthcare delivery. Medical practitioners, including physicians, specialists, and other healthcare professionals serve as key stakeholders by prescribing and recommending therapies to patients. In addition, Lupin engages with other pharmaceutical companies as B2B customers, supplying generic pharmaceutical products and active pharmaceutical ingredients through collaborations and commercial partnerships. IV. Employees 20. Details at the end of Financial Year: a. Employees and workers (including differently abled): The Company focuses on talent development through structured learning frameworks, internal mobility, succession planning and performance linked growth opportunities, supported by a strong culture of continuous learning and leadership development. Employment practices across manufacturing sites are underpinned by robust health and safety systems, statutory compliance and standardized processes. All workers are covered under comprehensive health and accident insurance, along with statutory benefits and operate within ISO 45001 certified occupational health and safety management systems. Regular training, worker engagement, and structured hazard identification mechanisms reinforce Lupin’s commitment to safe, compliant, and efficient shop floor operations. S. Total Male Female Particulars No. (A) No. (B) % (B/A) No. (C) % (C/A) EMPLOYEES 1 Permanent 20,113 18,718 93% 1,395 7% 2 Other than Permanent 897 568 63% 329 37% 3 Total employees 21,010 19,286 92% 1,724 8% WORKERS 4 Permanent 894 885 99% 9 1% 5 Other than Permanent 620 445 72% 175 28% 6 Total workers 1,514 1,330 88% 184 12% b. Differently-abled Employees and workers: Lupin’s approach to inclusion is anchored in equal opportunity, non-discrimination and accessibility. Workplaces are progressively designed to support differently-abled employees and workers through enabling infrastructure, appropriate role deployment and sustained sensitization initiatives. In parallel, Lupin is strengthening capacity building programmes focused on skills development, assistive enablement, and leadership readiness to empower more differently-abled resources to enter, thrive, and grow within the organization. Lupin’s Code of Conduct and people policies reinforce respect and dignity in the workplace, with a continued focus on embedding accessibility considerations into workforce planning, talent development and everyday workplace practices. S. Total Male Female Particulars No. (A) No. (B) % (B/A) No. (C) % (C/A) DIFFERENTLY-ABLED EMPLOYEES 1 Permanent 1 1 100% 0 0% 2 Other than Permanent 0 0 0% 0 0% 3 Total differently abled employees 1 1 100% 0 0% DIFFERENTLY-ABLED WORKERS 4 Permanent 1 1 100% 0 0% 5 Other than permanent 0 0 0% 0 0% 6 Total differently abled workers 1 1 100% 0 0% Business Responsibility and Sustainability Report 5 21. Participation/Inclusion/Representation of women Gender diversity is a strategic priority at Lupin and is actively driven across governance, leadership and the wider workforce. With 30% female representation on the Board and a formal diversity target of 15% women employees across the workforce by 2030, the organization continues to strengthen participation through inclusive hiring, leadership development programmes, equitable career progression and maternity support policies. No. and percentage of Total (A) Females No. (B) % (B/A) Board of Directors 10 3 30% Key Management Personnel 4* 1 25% *Includes executive directors who are also the Key Managerial Personnel of the Company. 22. Turnover rate for permanent employees and workers (Disclose trends for the past 3 years) Turnover trends for Lupin’s permanent employees and workers reflect a workforce that is becoming progressively more stable and engaged. The moderation in employee turnover aligns with sustained investments in learning, leadershi [Showing first 8,000 characters — download PDF for full document]